IE 11 is not supported. For an optimal experience visit our site on another browser.

Medicis Announces Availability of Online Proxy Materials for 2011

/ Source: GlobeNewswire

SCOTTSDALE, Ariz., April 6, 2011 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced that proxy materials are available via the Internet for its 2011 Annual Meeting of Stockholders under the U.S. Securities and Exchange Commission's (SEC) notice and access rule. Under this rule, the SEC provides companies the option of delivering a "Notice of Internet Availability of Proxy Materials" to stockholders, providing stockholders with Internet access to proxy materials, and providing a printed set of proxy materials to stockholders only upon request. Medicis proxy materials, including the Medicis 2010 annual report on Form 10-K and proxy statement, have been filed with the SEC, and may be accessed on the Company's website at Medicis stockholders may obtain hard copies of the Company's proxy materials free of charge by following the instructions provided on the Medicis website or in the "Notice of Internet Availability of Proxy Materials," which was mailed to stockholders today.

The Medicis 2011 Annual Meeting of Stockholders is scheduled for Tuesday, May 17, 2011, 9:30 a.m. (Pacific Time) at the Scottsdale Resort and Conference Center, 7700 East McCormick Parkway, Scottsdale, AZ 85258.

About Medicis

Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic conditions. The Company is dedicated to helping patients attain a healthy and youthful appearance and self-image. Medicis has leading branded prescription products in a number of therapeutic and aesthetic categories. The Company's products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance.

The Company's products include the brands DYSPORT® (abobotulinumtoxinA) 300 Units for Injection, PERLANE® Injectable Gel, PERLANE-L® Injectable Gel with 0.3% Lidocaine, RESTYLANE® Injectable Gel, RESTYLANE-L® Injectable Gel with 0.3% Lidocaine, DYNACIN® (minocycline HCl Tablets, USP), LOPROX® (ciclopirox) Gel 0.77% and Shampoo 1%, SOLODYN® (minocycline HCl, USP) Extended Release Tablets, VANOS® (fluocinonide) Cream, 0.1%, ZIANA® (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, AMMONUL® (sodium phenylacetate and sodium benzoate) Injection 10%/10%, BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, the LIPOSONIX™ system1 and the over-the-counter brand ESOTERICA®.

For more information about Medicis, please visit the Company's website at Printed copies of the Company's complete audited financial statements are available free of charge upon request.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. All statements included in this press release that address activities, events or developments that Medicis expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made by Medicis based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. No assurances can be given, however, that these activities, events or developments will occur or that such results will be achieved. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Medicis. Several of these risks are outlined in the Company's most recent annual report on Form 10-K for the year ended December 31, 2010, and other documents we file with the Securities and Exchange Commission. Forward-looking statements represent the judgment of Medicis management as of the date of this release, and Medicis disclaims any intent or obligation to update any forward-looking statements contained herein, which speak as of the date hereof.

NOTE: Full prescribing information for any Medicis prescription product is available by contacting the Company or by visiting . All trademarks are the property of their respective owners.

1 The LipoSonix system is not approved or cleared for sale in the U.S.

CONTACT: Medicis Kara Stancell (media) (480) 291-5454 Sean Andrews (investors) (480) 291-5854